4月28日,国家药品监督管理局药品审评中心(CDE)网站显示,百济神州的索托克拉片(sonrotoclax)申报上市。根据此前的优先审评记录,此次申报的适应症包括:①既往接受过抗CD20治疗和BTKi治疗的套细胞淋巴瘤(MCL)成人患者;②既往接受过治疗的慢性淋巴细胞白血病(CLL)/ 小淋巴细胞淋巴瘤(SLL)成人患者。索托克拉是百济神州开发的一款强效、高选择性BCL-2抑制剂,其设计旨在产生...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.